Welcome to our dedicated page for Argenx Se SEC filings (Ticker: ARGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The argenx SE (ARGX) SEC filings page on Stock Titan aggregates the company’s U.S. regulatory disclosures as a foreign private issuer. argenx files an annual report on Form 20-F and furnishes current information on Form 6-K, which often includes press releases, financial results, investor presentations and other updates related to its immunology business and the VYVGART franchise.
Through these filings, investors can review how argenx describes its role as a global immunology company focused on severe autoimmune diseases, its development and commercialization of the FcRn-blocking antibody fragment VYVGART, and the progress of its pipeline across generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), primary immune thrombocytopenia (ITP) in Japan and other autoimmune indications. Recent Form 6-K reports have attached press releases covering clinical trial outcomes, strategic priorities, preliminary financial results and shareholder meeting outcomes.
On this page, users can access filings that detail argenx’s product net sales, research and development expenses, selling, general and administrative expenses, and other financial metrics, as well as narrative explanations of its clinical programs and collaborations. Because argenx is listed on Nasdaq and Euronext, these documents provide insight into its obligations under U.S. securities law and its approach to disclosing material information.
Stock Titan enhances access to ARGX filings by pairing the raw SEC documents with AI-powered tools that help explain key sections of lengthy reports, such as annual Form 20-F disclosures and recurring Form 6-K updates. Users can quickly locate information on topics like VYVGART approvals, FcRn-focused research, pipeline candidates and capital markets activity, while also tracking how argenx’s immunology strategy is reflected over time in its official regulatory communications.
argenx SE filed a Form 6-K as a foreign private issuer to furnish investors with a new press release and an investor presentation dated October 30, 2025. These documents are attached as Exhibits 99.1 and 99.2 and provide updated company information for the market.
The furnished materials are also incorporated by reference into argenx’s existing Form S-8 registration statements, becoming part of those filings from the date this Form 6-K is filed, unless later superseded. This ties the latest investor communications directly into the company’s equity compensation registration framework.
Artisan Partners and affiliated entities report beneficial ownership of 2,349,776 American Depositary Shares of Argenx, representing 3.8% of the 61,166,252 ADS outstanding. The filing shows no sole voting or dispositive power; instead the filers report shared voting power of 2,010,189 ADS and shared dispositive power of 2,349,776. The reporting persons are Artisan Partners Asset Management Inc., Artisan Partners Holdings LP, Artisan Investments GP LLC and Artisan Partners Limited Partnership, all organized in Delaware with a principal business address in Milwaukee, WI.
The statement is made on Schedule 13G and includes a joint filing agreement among the reporting persons, and it certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.